Feasibility of Thioridazine as a Mobilizing Agent for CD34+ Hematopoietic Progenitor Cells

Inclusion Criteria: * Healthy, non-smoking subjects (male or female) * Age: 18 to 55 years * All subjects must agree to refrain from consuming alcohol during for 48 hours after taking thioridazine. * Performance status Karnofsky score of 100%. * Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. * A female of child-bearing potential is any woman (regardless of sexual orientation, having not undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: * Has not undergone a hysterectomy or bilateral oophorectomy; or has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months). * Ability to understand the purpose and procedures of this study, and the willingness to sign a written informed consent document. * Only subjects whose laboratory testing, including platelet counts and transaminase levels are within normal limits are eligible. * Subjects must pass pre-treatment screening by EKG to rule out long QT syndrome or subclinical cardiac arrhythmia. Exclusion Criteria: * Subjects who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to Agent(s) or other agents used in study. * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, a febrile illness within 35 days of study entry, or psychiatric illness or dementia, or social situations that would limit compliance with study requirements. * Subjects must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants. * Concomitant use of phenytoin excludes potential subjects from participation. * Subjects with known long QT syndrome or known history of cardiac arrhythmias are excluded from participation. * Subjects taking drugs known to inhibit P450 CYP2D6 are excluded from participation. * Subjects who received an investigational agent within 28 days of dosing with thioridazine on this protocol are excluded from participation. * Subjects who received thioridazine within 7 days of dosing on this protocol are excluded from participation. * Subjects who have had pelvic radiation are excluded from participation. * Subjects who have received myeloablative regimens at any time are excluded from participation.